$23.07
1.83% yesterday
Nasdaq, Nov 15, 10:00 pm CET
ISIN
US98401F1057
Symbol
XNCR

Xencor, Inc. Stock price

$23.07
+1.94 9.18% 1M
+1.78 8.36% 6M
+1.84 8.67% YTD
+4.15 21.93% 1Y
-14.38 38.40% 3Y
-12.91 35.88% 5Y
+11.93 107.09% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-0.43 1.83%
ISIN
US98401F1057
Symbol
XNCR
Sector
Industry

Key metrics

Market capitalization $1.64b
Enterprise Value $1.19b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 40.62
EV/Sales (TTM) EV/Sales 13.92
P/S ratio (TTM) P/S ratio 19.31
P/B ratio (TTM) P/B ratio 2.27
Revenue growth (TTM) Revenue growth -41.37%
Revenue (TTM) Revenue $85.16m
EBIT (operating result TTM) EBIT $-216.08m
Free Cash Flow (TTM) Free Cash Flow $29.18m
Cash position $542.98m
EPS (TTM) EPS $-3.20
P/E forward negative
P/S forward 28.09
EV/Sales forward 20.24
Short interest 11.78%
Show more

Is Xencor, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Xencor, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Xencor, Inc. forecast:

9x Buy
82%
1x Hold
9%
1x Sell
9%

Analyst Opinions

11 Analysts have issued a Xencor, Inc. forecast:

Buy
82%
Hold
9%
Sell
9%

Financial data from Xencor, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
85 85
41% 41%
100%
- Direct Costs 12 12
18% 18%
14%
73 73
46% 46%
86%
- Selling and Administrative Expenses 37 37
24% 24%
43%
- Research and Development Expense 240 240
0% 0%
281%
-204 -204
50% 50%
-239%
- Depreciation and Amortization 12 12
18% 18%
14%
EBIT (Operating Income) EBIT -216 -216
48% 48%
-254%
Net Profit -198 -198
67% 67%
-233%

In millions USD.

Don't miss a Thing! We will send you all news about Xencor, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xencor, Inc. Stock News

Neutral
Business Wire
9 days ago
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter ended September 30, 2024 and provided a review of recent business and clinical-stage program updates. “In September, we provided updates across our...
Neutral
Business Wire
12 days ago
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated dosing of healthy volunteers in the first-in-human study of XmAb®942, an investigational high-potency extended half-life anti-TL1A antibody. Xencor continues to ex...
Neutral
Business Wire
about one month ago
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that preclinical data on XmAb942 were published in a poster to be presented during United European Gastroenterology (UEG) Week on Tuesday, October 15 in Vienna, Austria. XmAb942 is a hi...
More Xencor, Inc. News

Company Profile

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Head office United States
CEO Bassil Dahiyat
Employees 280
Founded 1997
Website www.xencor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today